RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference May 21, 2015
Resverlogix and China-based Shenzhen Hepalink Pharmaceutical Co., Ltd. Announce a Combination Licensing and Equity Arrangement Apr 28, 2015
RepliCel Life Sciences Receives Approval to Conduct Clinical Trial for Patients with Chronic Achilles Tendinosis Apr 16, 2015
RepliCel Life Sciences Receives TSX Venture Exchange Approval to Extend Warrant Expiry Dates Apr 8, 2015
